Extended-Spectrum β-Lactamase–Producing Bacterial Infections in Adult Solid Organ Transplant Recipients

2011 ◽  
Vol 45 (3) ◽  
pp. 309-316 ◽  
Author(s):  
Holli A Winters ◽  
Rupal K Parbhoo ◽  
Jason J Schafer ◽  
Debra A Goff
Author(s):  
Judith A Anesi ◽  
Ebbing Lautenbach ◽  
Pranita D Tamma ◽  
Kerri A Thom ◽  
Emily A Blumberg ◽  
...  

Abstract Background Approximately 40% of all Enterobacterales (EB) bloodstream infections (BSIs) among solid organ transplant recipients (SOTRs) are due to extended-spectrum β-lactamase (ESBL)–producing organisms, but risk factors for such infections remain ill defined in this population. We sought to determine the risk factors for ESBL-EB BSIs among SOTRs. Methods A multicenter case-control study was performed. All SOTRs with an EB BSI at the Hospital of the University of Pennsylvania and University of Maryland Medical Center between 1 January 2007 and 30 June 2018 and at The Johns Hopkins Hospital between 1 January 2005 and 31 December 2015 were included. Cases were those with an ESBL-EB BSI. Controls were those with a non–ESBL-EB BSI. Multivariable logistic regression was performed to determine risk factors for ESBL-EB BSI. Results There were 988 episodes of EB BSI, of which 395 (40%) were due to an ESBL-EB. On multivariable analysis, the independent risk factors for ESBL-EB BSI included: ESBL-EB on prior culture (aOR, 12.75; 95% CI, 3.23–50.33; P < .001), a corticosteroid-containing immunosuppression regimen (aOR 1.30; 95% CI 1.03–1.65; P = .030), acute rejection treated with corticosteroids (aOR 1.18; 95% CI 1.16–1.19; P < .001), and exposure to third-generation cephalosporins (aOR 1.95; 95% CI 1.48–2.57; P < .001), echinocandins (aOR 1.61; 95% CI 1.08–2.40; P = .020), and trimethoprim-sulfamethoxazole (aOR 1.35; 95% CI 1.10–1.64; P = .003). Conclusions We identified several novel risk factors that are uniquely important to the SOTR population, including exposure to trimethoprim-sulfamethoxazole and corticosteroid-containing immunosuppressive regimens. Further studies exploring these associations and testing interventions aimed at these modifiable risk factors among SOTRs are needed.


Dermatology ◽  
2021 ◽  
pp. 1-6
Author(s):  
Efrat Solomon-Cohen ◽  
Shiran Reiss-Huss ◽  
Emmilia Hodak ◽  
Batya Davidovici

<b><i>Background:</i></b> Keratinocyte carcinomas, particularly squamous cell carcinoma (SCC), occur more frequently and aggressively in solid-organ transplant recipients (SOTRs) than in the general population. Systemic retinoids are effective in secondary prevention of keratinocyte carcinomas in this population, but their use is limited by adverse effects including a rebound effect in cases of treatment discontinuation. <b><i>Objective:</i></b> Our aim was to determine whether low-dose acitretin is efficient in the secondary prevention of keratinocyte carcinomas in SOTRs. <b><i>Methods:</i></b> This retrospective case-crossover study was conducted at a specialized dermatology clinic for SOTRs in a large transplantation center in 2010–2017. Patients with at least 1 previous keratinocyte carcinoma who were treated with acitretin 10 mg/day for 2 years were included. The main outcome was the difference in the number of new keratinocyte carcinomas diagnosed during treatment compared to during the 2-year pretreatment period. <b><i>Results:</i></b> The cohort included 34 SOTRs. A significant reduction in the mean number of new keratinocyte carcinomas during treatment relative to the pretreatment period was observed (1.7 vs. 3.6, –53% <i>p</i> = 0.002). Similar results were noted on analysis by tumor type, for both SCC and basal cell carcinoma. <b><i>Conclusion:</i></b> This study of SOTRs demonstrated positive results for low-dose acitretin as a chemoprevention of keratinocyte carcinomas in this population.


Sign in / Sign up

Export Citation Format

Share Document